Johnson & Johnson $JNJ Shares Sold by AEGON ASSET MANAGEMENT UK Plc

Key Points

• AEGON Asset Management UK cut its stake in Johnson & Johnson by 9.5% in Q4, selling 61,679 shares and leaving it with 585,592 shares worth about $121.19 million (JNJ is 1.4% of AEGON's holdings and its 14th largest position).
• Q1 results showed a slight beat with EPS of $2.70 versus $2.68 expected and revenue up 9.9% year‑over‑year, and the company reiterated FY2026 guidance of $11.45–$11.65 EPS.
• Dividend and analyst outlook: J&J raised its quarterly dividend to $1.34 ($5.36 annual, 2.4% yield), and analysts hold a consensus "Moderate Buy" rating with a $252.48 target (18 Buys, 9 Holds).

AEGON ASSET MANAGEMENT UK Plc cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 585,592 shares of the company's stock after selling 61,679 shares during the period. Johnson & Johnson makes up 1.4% of AEGON ASSET MANAGEMENT UK Plc's holdings, making the stock its 14th biggest holding. AEGON ASSET MANAGEMENT UK Plc's holdings in Johnson & Johnson were worth $121,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. WealthCollab LLC raised its stake in shares of Johnson & Johnson by 4.7% during the fourth quarter. WealthCollab LLC now owns 1,015 shares of the company's stock valued at $210,000 after acquiring an additional 46 shares during the last quarter. Vista Investment Partners II LLC raised its stake in shares of Johnson & Johnson by 1.2% during the fourth quarter. Vista Investment Partners II LLC now owns 3,811 shares of the company's stock valued at $789,000 after acquiring an additional 47 shares during the last quarter. Campbell Deegan Wealth Management LLC raised its stake in shares of Johnson & Johnson by 1.6% during the fourth quarter. Campbell Deegan Wealth Management LLC now owns 2,990 shares of the company's stock valued at $619,000 after acquiring an additional 48 shares during the last quarter. Finivi Inc. raised its stake in shares of Johnson & Johnson by 2.0% during the fourth quarter. Finivi Inc. now owns 2,458 shares of the company's stock valued at $509,000 after acquiring an additional 48 shares during the last quarter. Finally, Centennial Wealth Advisory LLC raised its stake in shares of Johnson & Johnson by 2.2% during the fourth quarter. Centennial Wealth Advisory LLC now owns 2,284 shares of the company's stock valued at $473,000 after acquiring an additional 49 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. The Goldman Sachs Group increased their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, April 15th. Rothschild & Co Redburn increased their price objective on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a research report on Thursday, February 19th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 15th. Bank of America increased their price objective on shares of Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 15th. Finally, Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $225.00 to $251.00 and gave the stock a "market perform" rating in a research report on Wednesday, April 15th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $252.48.

Johnson & Johnson Stock Down 0.2%

Johnson & Johnson stock opened at $227.30 on Thursday. Johnson & Johnson has a 1-year low of $146.12 and a 1-year high of $251.71. The firm has a market capitalization of $547.16 billion, a price-to-earnings ratio of 26.28, a price-to-earnings-growth ratio of 2.21 and a beta of 0.34. The firm's fifty day moving average price is $239.16 and its two-hundred day moving average price is $219.43. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. During the same period last year, the business earned $2.77 EPS. Johnson & Johnson's revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.4%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson's dividend payout ratio is presently 60.12%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA actions boost late‑stage and approved pipeline: the FDA granted Priority Review to IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia and approved a supplemental NDA for CAPLYTA (lumateperone) to prevent schizophrenia relapse — both expand J&J’s immunology and neuropsychiatry franchises and increase near‑ and mid‑term commercial optionality. FDA Decisions Put Johnson & Johnson’s Growth And Valuation In Focus
• Positive Sentiment: Cardiovascular M&A to broaden MedTech exposure: J&J agreed to buy Atraverse Medical to add the Hotwire left‑heart access system, supporting growth in atrial fibrillation and cardiac‑ablation markets and strengthening MedTech revenue mix. Johnson And Johnson Expands Heart Portfolio With Atraverse Deal And Valuation Upside
• Positive Sentiment: Analyst upgrades: Erste Group raised FY2026/2027 EPS forecasts for J&J (modest increases to $11.57 for FY2026 and $12.63 for FY2027), signalling improving analyst confidence in earnings trajectory. MarketBeat JNJ coverage
• Positive Sentiment: MedTech improvement continuing: management commentary and analyst notes point to sequential recovery in medical devices, supporting topline momentum in the higher‑margin MedTech segment. J&J Sees Continued MedTech Improvement in Q1, Eyes Better 2026
• Positive Sentiment: Dividend and quality recognition: J&J continues to be featured among dividend‑focused and quality stock lists (Dividend Kings/Reddit picks), which supports demand from income and defensive investors. 3 Dividend Kings That Have Outrun the Nasdaq Over 12 Months
• Neutral Sentiment: Quarterly results and guidance context: J&J reported a slight EPS beat for the quarter and reiterated FY2026 EPS guidance in the 11.45–11.65 range; steady fundamentals but not a dramatic surprise. MarketBeat JNJ coverage
• Neutral Sentiment: ETF/sector flow context: broader pharma/healthcare ETF and sector stories (Invesco PJP coverage) can influence relative flows into JNJ but are not company‑specific catalysts. Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
• Neutral Sentiment: Market focus / headlines: coverage noting J&J “gains focus” in the S&P can lift attention but not necessarily valuation immediately. Johnson & Johnson Gains Focus In S&P 500 today Watch
• Negative Sentiment: Recent share weakness and valuation scrutiny: analysts and writeups point to a ~6% one‑month pullback and renewed focus on valuation after short‑term underperformance, which can pressure sentiment and short‑term flows. A Look At Johnson & Johnson (JNJ) Valuation After Recent Share Price Weakness
• Negative Sentiment: Controversial distribution plan flagged: reports that J&J plans to sell some prescription drugs to TrumpRx as a cost‑reduction move introduce reputational and political risk that could concern some investors and payors. Johnson & Johnson Plans to Sell Prescription Drugs to TrumpRx in Cost-Reduction Push

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares in the company, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.